In human
somatotroph adenomas,
growth hormone (GH) hypersecretion can be inhibited by
somatostatin analogues such as
octreotide. Unfortunately, serum GH levels reach normal values in only 60% of treated patients. The decreased sensitivity to
octreotide is strongly related to a lower expression of
somatostatin receptor sst2. In this present study, the sst2 gene was transferred by an adenoviral vector (Ad-sst2) in human somatotroph (n = 7) and lactotroph (n = 2)
adenomas in vitro. Sst2
mRNA levels and sst2 immunostaining dramatically increased after
infection. Ten days after
infection at 20 multiplicity of
infection (MOI), sst2 gene transfer decreased cell viability from 19% to 90% by caspase-dependent apoptosis. At low viral doses (5 MOI), Ad-sst2 decreased GH or
prolactin (PRL) basal secretion and
mRNA expression. Somatotroph
tumors were classified in three groups according to their
octreotide sensitivity. Four days after
infection by 5 MOI Ad-sst2, the maximal GH suppression by
octreotide increased from 31% to 57% in the
octreotide partially resistant group and from 0% to 27% in the resistant ones. In the
octreotide-sensitive group, EC(50) values significantly decreased from 1.3 x 10(-11) to 6.6 x 10(-13) mol/L without improving maximal GH suppression. Finally, lactotroph
tumors, nonresponding to
octreotide in basal conditions, became
octreotide sensitive with a maximal PRL suppression of 43%
at 10(-8) mol/L. Therefore, sst2 reexpression is able to improve
octreotide sensitivity. Sst2 gene transfer may open new therapeutic strategies in treatment combined with
somatostatin analogues.